with Division Office

Research Project

We are developing technologies that utilize non-damaging nanomaterials for the analysis and manipulation of living cells and organoids. This research is based on cell mechanics, which involves measuring forces from piconewtons to micronewtons using atomic force microscopy (AFM) to investigate interactions between antibodies and target membrane proteins, as well as the elasticity and adhesion forces of living cells. Specifically, our work includes genome editing using nanoneedles with a diameter of 200 nm, the construction of novel cancer models, and the development of therapeutic antibody drugs.

• https://unit.aist.go.jp/cmb5/chikashi-nakamura/index.html

The advancement of bioassays for evaluating the safety and functionality of compounds is an urgent challenge. Traditionally, the evaluation of “biosystems”—referring to the mechanisms of biological responses, including physiological functions—has primarily relied on animal testing. However, a global shift toward alternative technologies is now underway, highlighting the need to establish a new academic research field tentatively referred to as biosystem replacement science. We are developing next-generation evaluation platforms with high human relevance, predictability, and reproducibility by integrating New Approach Methodologies (NAMs), omics analysis, and in silico simulations.

This research aims to build advanced evaluation systems that replicate the human physiological environment by integrating microphysiological systems (MPS) with diverse cells and tissues. These systems enable the analysis of physiological responses and drug mechanisms involving the autonomic nervous, immune, and vascular systems—areas difficult to assess with conventional models.

We combine MPS-based NAMs (New Approach Methodologies) with digital technologies such as omics data analysis and in silico simulations to develop predictive, data-driven safety assessment systems. Human iPS cells, along with those derived from animals like rats, mice, and rabbits, are used to create alternative evaluation platforms and cross-species comparative models. Our platform extends beyond pharmaceuticals and food, targeting chemical safety evaluation in housing and consumer products through in vitro × in silico approaches.

By enhancing prediction accuracy without relying on animal testing, we aim to support faster regulatory processes and more reliable product development. These technologies also contribute to the advancement and sustainability of bio-manufacturing and the wider bioeconomy.